Semaglutide reduces osteoarthritis by activating cell cleanup processes through GLP-1 receptors, independent of weight loss

The study aims to evaluate the therapeutic potential of semaglutide in osteoarthritis (OA).

• Semaglutide is a long-acting glucagon-like peptide-1 receptor (GLP-1R) agonist commonly used for diabetes management.
• Osteoarthritis is closely associated with systemic metabolic disorders.
• There is currently a lack of disease-modifying therapies that address both metabolic abnormalities and inflammation in OA.
• The study seeks to investigate the underlying molecular mechanisms of semaglutide's effects on OA.

Simplified